Darwin Discovery Limited

Chiroscience, Ltd.

Pfizer Corporation

Sosei R&d Ltd.

Biocopea Limited

Andrew Douglas Baxter

John Gary Montana

David Alan Owen

Robert John Watson

Hazel Joan Dyke

Duncan Robert Hannah

John Fraser Keily

Andrew Sharpe

David Hepworth

Charlotte Moira Norfor Allerton

Andrew Simon Cook

Stephen Kwok-Fung Wong

Duncan Batty

Robin Mark Bannister

John Brew

Alan Findlay Haughan

Verity Margaret Sabin

George Martin Buckley

Richard John Davenport

Steven Colin Beasley

Neil Phillipson

David James Rawson

Justin Stephen Bryans

Kevin Neil Dack

Russell Andrew Lewthwaite

Patrick Stephen Johnson

Thomas Ryckmans

Hannah Jayne Kendall

David Thomas Manallack

Julie Newman

Karen Ann Runcie

Robert James Maxey

Andrea Walmsley

Elizabeth Jane Reed Nicholson

Robert Duncan Armour

Jonathan Dickens

Hazel John Dyke

Kenneth Walter Sinden

Stefan Kleinebekel

John Bird

Ruth Elizabeth Wills

Charlotte Moira Allerton

A method for the production of crystalline glycopyrronium bromide, comprises the reaction of glycopyrronium base with methyl bromide in a solvent, in which the solvent is selected such that the diastereoisomeric ratio of the product favors the R,S and S,R diastereoisomers over the R,R, and S,S diastereoisomers, and separating the desired diastereoisomers by one or more controlled crystallization steps. This method gives a product having a particle size of narrow distribution.

Crystallisation and purification of glycopyrronium bromide

A compound for therapeutic use, of the formula (I), wherein Ris aryl or heteroaryl optionally substituted with R; Ris H, alkyl or CHOH or forms part of a ring with R; Ris H, alkyl or CHOH or forms part of a ring with R; Ris H, alkyl or (when forming part of a ring with Ror R) CH; and Ris alkyl, CF, OH, Oalkyl, OCOalkyl, CONH, CN, halogen, NH, NO, NHCHO, NHCONH, NHSOMe, CONH, or SOMe; or a salt thereof. 

Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain

Compounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (I) or a salt thereof.

Use of bupropion metabolites for the treatment of inflammatory disorders

A glycopyrronium salt such as glycopyrronium iodide has a lower glass transition temperature than glycopyrronium bromide. It is therefore more suitable for formulation.

Glycopyrronium salts and their therapeutic use

The present invention provides for compounds of formula (I), (Ia) and (Ib) Wherein:

Morpholine dopamine agonists

Compounds that may have anti-inflammatory activity are of general formula (I); wherein X, is H or COR, and Xis H or CORbut X, and Xare not both H; Rand Rare the same or different and are each Calkyl substituted with R, or a four to seven-membered ring which can be optionally substituted with Rand can contain one or more additional heteroatoms selected from O, S(O)and NR; is Ris F, CF, OR, NRRO, S(O)R; R, Rand Rare the same or different and are each H or Calkyl optionally substituted with R, or NRRis a Cheterocycloalkyl ring containing one or more heteroatoms selected from O, NRand S(O); each n is 0-2; Ris Calkyl; Ris as defined for Ror Calkyl optionally substituted with Ror halogen; and Ris H or Calkyl; or a salt, solvate or hydrate thereof. 

Ester derivatives of rhein and their therapeutic use

Compounds of formula (I), (Ia) and (Ib) useful as a medicament.

The invention provides compounds of formula (I), the pharmaceutically acceptable salts and solvates thereof, wherein A, B, R, R, and Rare as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof as vasopressin Vantagonists.

Triazole compounds useful in therapy

Pharmacologically active compounds are provided as well as pharmaceutical compositions and methods for treating cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration in a mammal.

Hydroxamic and carboxylic acid derivatives

The subject invention pertains to matrix metalloproteinase (MMP) inhibitors that exhibit an IC of below 10 M against MMP and have substantially no activity against non-MMP metalloproteinase-related events. The MMP inhibitors of the invention have reduced side-effects, especially with respect to joint pain.

Selective MMP inhibitors having reduced side-effects

The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.

Hydroxamic acid derivatives

4-(4-(-Chlorophenyl)piperazin-1-yl)sulfonylmethyl)-tetrahydor yran-4-carboxylic acid and the corresponding N-hydroxy amide, and derivatives thereof, are useful as therapeutic agents.

Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity

Growing community of inventors

Cambridge, United Kingdom

Andrew Douglas Baxter